Anixa Biosciences Files 8-K

Ticker: ANIX · Form: 8-K · Filed: Mar 22, 2024 · CIK: 715446

Anixa Biosciences Inc 8-K Filing Summary
FieldDetail
CompanyAnixa Biosciences Inc (ANIX)
Form Type8-K
Filed DateMar 22, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, filing, financials

TL;DR

Anixa Biosciences filed an 8-K on 3/21/24 covering votes, Reg FD, and financials.

AI Summary

Anixa Biosciences, Inc. filed an 8-K on March 21, 2024, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements. The company, formerly known as ITUS Corp and COPYTELE INC, is incorporated in Delaware and headquartered in San Jose, California.

Why It Matters

This filing provides an update on corporate governance and financial reporting for Anixa Biosciences, Inc., which is relevant for investors tracking the company's regulatory compliance and operational status.

Risk Assessment

Risk Level: low — This is a routine 8-K filing detailing corporate actions and financial reporting, not indicating any immediate material adverse events.

Key Numbers

  • 001-37492 — SEC File Number (Identifies the company's filing history with the SEC.)
  • 11-2622630 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • Anixa Biosciences, Inc. (company) — Registrant
  • ITUS Corp (company) — Former company name
  • COPYTELE INC (company) — Former company name
  • Delaware (jurisdiction) — State of incorporation
  • San Jose, CA (location) — Principal executive offices
  • March 21, 2024 (date) — Date of earliest event reported

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in this excerpt.

What is the primary business of Anixa Biosciences, Inc.?

Anixa Biosciences, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.

When was Anixa Biosciences, Inc. formerly known as ITUS Corp?

The date of the name change from ITUS Corp was September 2, 2014.

What is the company's fiscal year end?

The company's fiscal year ends on October 31.

Where are Anixa Biosciences, Inc.'s principal executive offices located?

The principal executive offices are located at 3150 Almaden Expressway, Suite 250, San Jose, CA 95118.

Filing Stats: 788 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2024-03-22 16:30:40

Key Financial Figures

  • $0.01 — ch registered Common Stock, par value $0.01 per share ANIX The NASDAQ Stock Mar

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 22, 2024 ANIXA BIOSCIENCES, INC. By: /s/ Michael J. Catelani Name: Michael J. Catelani Title: President, Chief Operating Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.